China’s drug regulator has accepted Nicox’s NDA for NCX 470, putting a nitric oxide-donating glaucoma drop one formal review cycle away from a potential approval in one of the world’s largest ophthalmology markets. That acceptance matters because the NCX 470 program has already run two pivotal Phase 3 trials, DENALI and MONT BLANC, and the China filing draws on that clinical package rather than requiring a separate local trial program from scratch.
NCX 470 is a second-generation bimatoprost eye drop that donates nitric oxide, which adds trabecular outflow enhancement on top of the uveoscleral mechanism bimatoprost already provides. In the DENALI trial, NCX 470 0.1% met non-inferiority against latanoprost 0.005%, with mean IOP reductions from baseline reaching into the 7-plus mmHg range across measured timepoints. That two-mechanism profile is the competitive argument Nicox is making, and it now gets tested against the National Medical Products Administration’s review standard rather than the FDA’s.
The NMPA acceptance does not guarantee a smooth path. China’s standard review clock for a new chemical entity typically runs 200 working days once an application is accepted, though priority designations can shorten that window. Nicox has not disclosed whether NCX 470 received priority status in China, so the standard timeline is the working assumption. The company’s ability to sustain operations through that review period is the real watch item: Nicox is a small French biotech, and the gap between NDA acceptance and commercial revenue in a new geography puts pressure on its cash runway regardless of how the clinical data read.
The China acceptance also arrives while the U.S. regulatory path for NCX 470 remains unresolved. NMPA’s 2022 registration provisions allow for a parallel review process independent of FDA action, so Chinese approval is not contingent on U.S. clearance. Whether Nicox can convert an NMPA green light into a commercial partnership in China, and on what economic terms, is the decision that will actually determine whether the regulatory milestone translates into shareholder value.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
